Latest News on IBRX

Financial News Based On Company


Advertisement
Advertisement

ImmunityBio Ranks No. 2 on 2026 Deloitte Technology Fast 500 With Over 47,000% Revenue Growth

https://www.citybiz.co/article/936581/immunitybio-ranks-no-2-on-2026-deloitte-technology-fast-500-with-over-47000-revenue-growth/
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, has secured the No. 2 position on the 2026 Deloitte Technology Fast 500 list, reporting over 47,000% revenue growth between 2022 and 2025. This significant achievement is attributed to the growing commercialization of ANKTIVA, its immunotherapy for non-muscle invasive bladder cancer. The company continues to expand patient access and strengthen its global commercial presence, demonstrating sustained momentum with 92% growth through the first nine months of 2026.

ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-named-no-2-fastest-growing-technology-company-north
ImmunityBio, Inc. (NASDAQ: IBRX) has been recognized as the No. 2 fastest-growing technology company in North America on the 2026 Deloitte Technology Fast 500, demonstrating over 47,000% revenue growth from 2022 to 2025. This achievement highlights the expanding global adoption of its immunotherapy ANKTIVA®, with the company sustaining significant net product revenue growth into 2026. The ranking reflects ImmunityBio's focus on patient access, commercial presence, and delivering stockholder value through its innovative Cancer BioShield™ platform.

Why ImmunityBio (IBRX) Stock Is Up 7.0% And What's Next After Bladder Cancer Trial Results

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/why-immunitybio-ibrx-stock-is-up-70-and-whats-next-after-bla
ImmunityBio (IBRX) stock rose 7.0% after reporting Q3 2026 results and positive statistically significant efficacy results for ANKTIVA plus BCG in a bladder cancer trial. This development positions ANKTIVA for an earlier-stage bladder cancer market, with an upcoming FDA filing and new approval in Israel. The company aims to scale its commercial business despite ongoing heavy R&D and operating costs, with analysts projecting significant revenue and earnings growth by 2029.

ImmunityBio (IBRX) Could Be 56% Below Fair Value Following ANKTIVA Trial And Launch News

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-could-be-56-below-fair-value-following-ankt
ImmunityBio (IBRX) has reported positive final results from its QUILT-2.005 bladder cancer trial and secured ANKTIVA approvals and commercial treatments in Israel and Europe. Despite a recent pullback, analysts estimate the company's fair value at $14.25, significantly higher than its current price of $6.26, suggesting it is 56% undervalued. However, the stock trades at a high P/S ratio of 36.5x, indicating investors are already factoring in future execution.

ImmunityBio Stock Extends A 6-Day Losing Streak To A 31% Loss

https://www.trefis.com/stock/ibrx/articles/625568/immunitybio-stock-extends-a-6-day-losing-streak-to-a-31-loss/2026-11-17
ImmunityBio (IBRX) stock has experienced a 6-day losing streak, plummeting 30.7% and erasing approximately $2.8 billion from its market value. Despite the significant drop, the article notes that the S&P 500 returned positively over the same period, suggesting the decline is company-specific. ImmunityBio's fundamentals show strong revenue growth but a negative operating margin, providing some support for the sellers.
Advertisement

Key facts: ImmunityBio bladder trial meets endpoint; Q3 sales rise 53%

https://www.tradingview.com/news/tradingview:5858d0d4c8735:0-key-facts-immunitybio-bladder-trial-meets-endpoint-q3-sales-rise-53/
ImmunityBio (IBRX) announced that its Quilt-2.005 trial, evaluating Anktiva plus BCG for high-grade, BCG-naive bladder cancer, successfully met its endpoint with a p-value of 0.01; full results are pending. Additionally, the company reported a significant 53% year-over-year increase in third-quarter sales, reaching approximately $49 million.

A 5-Day Losing Streak Has ImmunityBio Stock Down 30%

https://www.trefis.com/stock/ibrx/articles/625132/a-5-day-losing-streak-has-immunitybio-stock-down-30/2026-11-14
ImmunityBio (IBRX) stock has experienced a significant 30.3% decline over a 5-day losing streak, erasing about $2.8 billion from its market value. This slide appears to be company-specific rather than a broader market movement, as the S&P 500 saw a positive return during the same period. Despite substantial revenue growth, the company's negative operating margin indicates a fundamental weakness supporting the sell-off.

Biotech Insider Activity Cuts Both Ways: ImmunityBio Directors Cash Out Over NT$1.4 Billion While One Insider Bought Just Before a 5x Rally

https://finance.biggo.com/news/5c7a1d0c-18e3-4e89-bfb5-72593a5f35ac
Insider trading activity in U.S. biotech stocks presents a divided picture, with directors at ImmunityBio and executives at Capricor selling nearly $18 million in shares, primarily after exercising options or under pre-arranged plans. Conversely, a director at Sellas Life Sciences made a timely open-market purchase, seeing her investment surge by 430%. Meanwhile, insiders at Iovance Biotherapeutics remained inactive in open-market transactions, focusing on increasing sales of their melanoma therapy, Amtagvi.

Is ImmunityBio (IBRX) Getting Too Rich For Its Sales Story?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/is-immunitybio-ibrx-getting-too-rich-for-its-sales-story
ImmunityBio (IBRX) has seen a significant 233.5% share price increase over the past year, raising questions about whether its current valuation is justified by its sales. The company's P/S ratio of 38.9x is considerably higher than the biotech industry average, suggesting it may be overvalued based on current sales. Despite recent positive developments with ANKTIVA, investors are cautioned to consider the company's future product uptake and funding plans before viewing the current P/S level as reasonable.

ImmunityBio, Inc. (26CA.F) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/26CA.F/seasonality/
This Yahoo Finance article presents the seasonal returns chart for ImmunityBio, Inc. (26CA.F), showing the average monthly price return from 2021 to 2026. The stock closed at 6.02 EUR, down 4.75% on November 10.
Advertisement

ImmunityBio's Anktiva sales rise 53% from a year ago but slip from the second quarter

https://mlq.ai/news/immunitybios-anktiva-sales-rise-53-from-a-year-ago-but-slip-from-the-second-quarter/
ImmunityBio reported a 53% increase in Anktiva sales year-over-year to $48.7 million for the third quarter, with nine-month sales up 92% to $143.6 million. However, total revenue of $48.8 million was a slight decrease from the second quarter's $51.2 million. The company's net loss widened significantly to $184.6 million, primarily due to non-cash fair-value changes tied to a rising share price.

ImmunityBio Q3 2026: A $77.9M Charge Masks Real ANKTIVA Progress

https://247wallst.com/cards/immunitybio-q3-2026-earnings-ibrx-01m705c5jsxsxw0n7y6sjvtmg7
ImmunityBio reported a significant Q3 2026 loss of $0.18 per share, primarily driven by a $77.9 million non-cash charge related to fair-value changes in a convertible note, despite a 52% year-over-year revenue increase to $48.84 million. The company's bladder cancer immunotherapy, ANKTIVA, showed strong operational growth with a 53% revenue gain and a recent FDA label expansion. A key near-term catalyst is a planned Q4 2026 supplemental BLA submission for a BCG-naive bladder cancer indication.

ImmunityBio Stock Tumbles 19% as Q3 Revenue Misses, Despite Bladder Cancer Trial Win

https://finance.biggo.com/news/89bb8faf-504f-4275-a5fa-a6a3d6dab387
ImmunityBio's stock dropped nearly 19% after the company reported third-quarter revenue of $48.8 million, missing the $59.2 million consensus, and an adjusted loss of 9 cents per share. This financial miss overshadowed positive news about its Anktiva plus BCG treatment meeting the primary endpoint in a bladder cancer trial and gaining approval in Israel. Despite the recent tumble, the stock remains up over 280% for the year, highlighting the company's clinical progress amidst financial challenges.

ImmunityBio Reports Wider Quarterly Loss

https://www.tradingview.com/news/benzinga:84b0a59ae094b:0-immunitybio-reports-wider-quarterly-loss/
ImmunityBio Inc. reported a wider-than-expected adjusted loss of 9 cents per share for its third quarter, missing the consensus estimate of 8 cents, with sales also falling short at $48.84 million. Despite the financial miss, the company's ANKTIVA treatment reached its primary endpoint in a bladder cancer trial and received accelerated authorization from the Israeli Ministry of Health. ImmunityBio stock declined over 25% following the earnings release.

Immunitybio Inc earnings missed by $0.10, revenue fell short of estimates

https://www.investing.com/news/earnings/immunitybio-inc-earnings-missed-by-010-revenue-fell-short-of-estimates-5012708
Immunitybio Inc (NASDAQ: IBRX) reported third-quarter EPS of $-0.18, missing analyst estimates by $0.10, and revenue of $48.84M, falling short of the consensus estimate of $59.23M. Despite the earnings miss, Immunitybio Inc's stock has shown strong performance, rising 12.94% in the last 3 months and 206.48% in the last 12 months, with its financial health rated as "good performance" by InvestingPro.
Advertisement

Why Is ImmunityBio Stock Trading Lower On Monday? - ImmunityBio (NASDAQ:IBRX)

https://www.benzinga.com/markets/earnings/26/11/63041433/immunitybio-reports-wider-quarterly-loss
ImmunityBio Inc. (NASDAQ: IBRX) stock declined on Monday after reporting third-quarter earnings that missed analyst expectations, with an adjusted loss of 9 cents per share and sales of $48.84 million, both below consensus estimates. The company's net loss widened significantly due to derivative adjustments and increased R&D and SG&A expenses. Despite the financial miss, ImmunityBio announced positive final results from its ANKTIVA bladder cancer trial and received accelerated approval for ANKTIVA in Israel.

ImmunityBio posts 53% revenue gain as ANKTIVA wins label expansion

https://www.streetinsider.com/Corporate+News/ImmunityBio+posts+53%25+revenue+gain+as+ANKTIVA+wins+label+expansion/27311312.html
ImmunityBio (NASDAQ: IBRX) reported a 53% increase in net product revenue for the third quarter of 2026, reaching $48.7 million, with a 92% increase for the first nine months. The company's ANKTIVA drug received expanded FDA approval for non-muscle invasive bladder cancer and was also approved in Israel, bringing its global approvals to 35 countries. Despite the revenue growth, ImmunityBio reported a significant GAAP net loss due to non-cash fair value changes and increased operating expenses.

ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-label-expansion-and-additional-global
ImmunityBio announced significant progress in Q3 2026, including an expanded FDA approval for ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer, now including papillary-only tumors. The company also reported meeting the primary endpoint for BCG-naïve NMIBC and achieved global expansion with ANKTIVA approval in Israel and the first European patients treated. Financially, net product revenue surged to $48.7 million for Q3 2026, up 53% year-over-year, and $143.6 million for the first nine months, a 92% increase, driven by strong U.S. adoption and market access.

ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

https://finance.yahoo.com/healthcare/articles/immunitybio-rafa-announce-israeli-ministry-120000146.html
ImmunityBio and Rafa Laboratories announced that the Israeli Ministry of Health has approved ANKTIVA® (nogapendekin alfa inbakicept) in combination with BCG for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. This approval, granted four months after submission, marks a significant milestone in providing a new chemotherapy-free immunotherapy option for patients in Israel. Rafa will be the exclusive commercialization partner for ANKTIVA in Israel, addressing a high unmet medical need for bladder cancer treatment in the region.

Form 8-K ImmunityBio, Inc. For: Nov 09

https://www.streetinsider.com/SEC+Filings/Form+8-K+ImmunityBio%2C+Inc.+For%3A+Nov+09/27310703.html
ImmunityBio, Inc. filed a Form 8-K on November 9, 2026, announcing that its ANKTIVA® plus Bacillus Calmette-Guérin (BCG) treatment met the primary endpoint in Cohort A of the QUILT-2.005 trial for BCG-naïve non-muscle invasive bladder cancer. The press release detailing this achievement is furnished as Exhibit 99.1 to the report.
Advertisement

IBRX: ImmunityBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

https://www.quantisnow.com/insight/immunitybio-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6779989
ImmunityBio Inc. announced via an SEC Form 8-K filing that its ANKTIVA plus BCG combination met the primary efficacy endpoint in Cohort A of the randomized QUILT-2.005 trial for BCG-naive non-muscle invasive bladder cancer. The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026 to expand ANKTIVA's approved use. Shareholders should note that while positive, full trial data are still pending presentation at a medical congress, and regulatory approval is subject to review.

A bladder cancer combination worked better than standard care in a 370-patient trial

https://www.stocktitan.net/news/IBRX/immunity-bio-announces-anktiva-plus-bcg-meets-primary-endpoint-in-912nnt005svb.html
ImmunityBio announced positive results from its QUILT-2.005 trial, showing that ANKTIVA plus BCG significantly improved efficacy compared to BCG alone in patients with BCG-naïve, high-grade non-muscle invasive bladder cancer. This chemotherapy-free immunotherapy combination maintained patient-reported quality of life and showed no treatment-related deaths. A supplemental Biologics License Application (sBLA) is planned for submission to the FDA by year-end 2026 to expand ANKTIVA's indication.

ImmunityBio’s Anktiva meets trial goal for bladder cancer

https://www.investing.com/news/company-news/immunitybios-anktiva-meets-trial-goal-for-bladder-cancer-93CH-5011359
ImmunityBio Inc. announced that its trial for Anktiva plus BCG met the primary efficacy endpoint in treating patients with BCG-naïve non-muscle invasive bladder cancer. The combination therapy showed statistically significant improvement over BCG alone, with no new safety concerns. The company plans to submit a supplemental Biologics License Application to the FDA by year-end 2026 to expand Anktiva's indication.

Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial

https://www.businesswire.com/news/home/20261109448906/en/ImmunityBio-Announces-ANKTIVA-Plus-BCG-Meets-Primary-Endpoint-in-BCG-Nave-Non-Muscle-Invasive-Bladder-Cancer-Randomized-QUILT-2.005-Trial
ImmunityBio announced positive results from the QUILT-2.005 trial, where ANKTIVA plus BCG met its primary endpoint in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC). The chemotherapy-free combination showed a statistically significant improvement in efficacy compared to BCG alone, with a maintained patient-reported quality of life and no treatment-related deaths. The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026, potentially expanding ANKTIVA's indication to an earlier stage of the disease.

ImmunityBio reports Anktiva endpoint success in BCG‑naïve bladder cancer

https://mugglehead.com/immunitybio-anktiva-bcg-naive-quilt-primary-endpoint/
ImmunityBio announced that its Anktiva plus BCG combination therapy met its primary endpoint in a Phase 2b trial for BCG-naïve bladder cancer patients, showing improved efficacy over BCG alone. The company, however, withheld specific response rates and detailed statistical data, although it confirmed no new safety concerns. ImmunityBio plans to submit a supplemental biologics license application to the FDA by year-end 2026 to expand Anktiva's indication for earlier treatment.
Advertisement

ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

https://www.quantisnow.com/insight/immunitybio-and-rafa-announce-israeli-ministry-of-health-approval-of-6780085
ImmunityBio and Rafa Laboratories have announced that the Israeli Ministry of Health has approved ANKTIVA® Plus BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. This approval, granted four months after submission, establishes Rafa Laboratories as the exclusive commercial partner in Israel, expanding ANKTIVA's market presence to 35 countries. The registration license is expected within weeks, offering a bladder-preserving treatment option for patients.

ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment

https://ca.finance.yahoo.com/news/immunitybio-shares-slump-19-revenue-164400415.html
ImmunityBio Inc. (NASDAQ:IBRX) shares fell 19% after the company reported a third-quarter revenue shortfall and a significantly wider net loss, missing analyst expectations. The company also raised concerns about its ability to continue as a going concern without additional funding, despite positive developments for its bladder cancer treatment, ANKTIVA.

ImmunityBio stock: Friday evening quote from Lang & Schwarz

https://www.ad-hoc-news.de/boerse/news/corporate-news/immunitybio-stock-friday-evening-quote-from-lang-schwarz/70472270
ImmunityBio stock was quoted at 7.69 euros on Lang & Schwarz on Friday evening, November 6, 2026. The biotechnology company, which focuses on developing therapies and vaccines for cancer and infectious diseases, has several candidates in Phase II or Phase III clinical development. Investors can access real-time quotes for IBRX, which operates in the healthcare and biotechnology sectors.

ImmunityBio (IBRX) Starts Europe Rollout Following ANKTIVA Milestone But Is The Valuation Already Priced In

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-starts-europe-rollout-following-anktiva-mil
ImmunityBio (IBRX) has begun its European rollout of ANKTIVA for BCG unresponsive non-muscle invasive bladder cancer after receiving conditional European Commission approval. Despite recent share price volatility, the stock shows a 296.5% year-to-date return, with analysts pegging its fair value at $14.25 compared to its last close of $8.01, suggesting it is undervalued. The company's rapid global expansion of ANKTIVA into 33 countries aims to address a significant treatment gap and drive future revenue growth, though risks remain if it becomes the sole revenue driver or if regulatory hurdles prove challenging.

ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

https://www.biospace.com/press-releases/immunitybio-announces-first-patients-in-europe-treated-with-anktiva-plus-bcg-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ
ImmunityBio has announced that the first patients in Europe have been treated with ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer. This milestone follows the European Commission's conditional marketing authorization in February 2026 and marks a significant step in expanding patient access to this treatment across Europe, with initial treatments administered in Germany and Austria. The company is collaborating with Accord Healthcare for commercial support and Uniphar for supply chain and distribution services to ensure ANKTIVA's availability.
Advertisement

ImmunityBio (IBRX) Begins First European Treatments For Bladder Cancer

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-begins-first-european-treatments-for-bladde
ImmunityBio (IBRX) has initiated treatments for BCG-unresponsive bladder cancer patients in Europe with ANKTIVA plus BCG, following conditional marketing authorization. This marks the company's first clinical and commercial expansion for ANKTIVA outside the U.S., starting in Germany and Austria. The success of this rollout hinges on sustained treatment volumes and uptake across additional EU countries to translate conditional approval into recurring demand.

ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings

https://stocktwits.com/news-articles/markets/equity/immunitybio-treats-first-patients-in-europe-with-anktiva-plus-bcg/cNGLh8FR93N
ImmunityBio (IBRX) announced that the first patients in Europe have received its bladder cancer treatment, Anktiva, combined with Bacillus Calmette-Guérin (BCG), following conditional approval from the European Commission in February 2026. Treatments began in Germany and Austria for patients with BCG-unresponsive non-muscle invasive bladder cancer. The company expects to report its third-quarter results soon, with Wall Street anticipating $59.2 million in revenue and a loss of $0.08 per share.

ImmunityBio Announces First Patients in Europe Treated with ANKTI

https://natlawreview.com/press-releases/immunitybio-announces-first-patients-europe-treated-anktivar-plus-bcg-bcg
ImmunityBio announced that the first patients in Europe have been treated with ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer, following conditional marketing authorization from the European Commission in February 2026. Treatments were administered in Germany and Austria, with commercial support from Accord Healthcare and supply chain services from Uniphar, aiming to expand access to this new therapy across Europe. This marks a significant milestone for patients with unmet medical needs in the region, offering an alternative to radical cystectomy.

ImmunityBio's Anktiva treats first European bladder cancer patients

https://www.streetinsider.com/Corporate+News/ImmunityBios+Anktiva+treats+first+European+bladder+cancer+patients/27286347.html
ImmunityBio, Inc. announced that the first patients in Europe have been treated with ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. This milestone follows the European Commission's conditional marketing authorization of ANKTIVA in February 2026. Salzburg University Hospital in Austria was the first center in Europe to administer the treatment, addressing a critical unmet need as no approved treatment options previously existed in the EU for these patients.

Trial Data Review Could Be A Key Test For ImmunityBio Stock (IBRX)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/trial-data-review-could-be-a-key-test-for-immunitybio-stock
ImmunityBio's QUILT-2.005 registrational trial for BCG-naïve NMIBC has reached database lock for Cohort A, allowing for final efficacy analysis on 366 patients. This development is crucial as it could expand the ANKTIVA bladder cancer franchise into earlier treatment pathways, building on previous FDA-requested interim data showing statistically significant longer complete response duration. The outcome of this data review will be a key test for ImmunityBio's strategy to diversify beyond its current commercial activity and validate its broader immunotherapy platform.
Advertisement

Immunitybio (IBRX) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/IBRX.US
This article provides a detailed analysis of Immunitybio (IBRX) stock, covering its current price, market capitalization, quality score, and growth metrics. It highlights that Immunitybio does not pay dividends and that its revenue is growing, but it has not made a profit in the last twelve months. The analysis also includes a "Belegger score" based on Buffett and Lynch methodologies, alongside various financial ratios and analyst price targets.

Weekly Recap: Quilt-2.005 review completed and Anktiva approval expanded

https://www.tradingview.com/news/tradingview:9c714ebed2daa:0-weekly-recap-quilt-2-005-review-completed-and-anktiva-approval-expanded/
ImmunityBio Inc (IBRX) received expanded FDA approval for Anktiva in combination with BCG for papillary-only bladder cancer. The company also completed data review for its Quilt-2.005 trial, with results expected in November and an FDA application planned for Q4. Shares saw a slight increase after Jim Cramer commented positively on the stock.

IBRX Stock Climbs Overnight: Founder Calls Sepsis Push ‘Unstoppable’ As Trials Near — Teases NantX After Crypto Heist

https://www.tradingview.com/news/stocktwits:d3a5c0939094b:0-ibrx-stock-climbs-overnight-founder-calls-sepsis-push-unstoppable-as-trials-near-teases-nantx-after-crypto-heist/
Shares of ImmunityBio (IBRX) climbed nearly 1% overnight after founder Patrick Soon-Shiong highlighted plans to test its immunotherapy, Anktiva, in sepsis, expanding its potential beyond cancer. He also renewed his "NantX coming soon" teaser for a financial technology initiative after a significant crypto theft. Despite a recent stock dip, retail sentiment on Stocktwits remains divided, with some seeing great potential in the sepsis trials.

ImmunityBio Inc (26CA.SG) Seasonal returns chart

https://uk.finance.yahoo.com/quote/26CA.SG/seasonality/
The article presents a seasonal returns chart for ImmunityBio Inc (26CA.SG), showing the average monthly price return from 2021 to 2026. As of July 23, the stock was trading at 5.22 EUR, up 1.12%.

IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat

https://stocktwits.com/news-articles/markets/equity/ibrx-retail-strong-anktiva-sales-earnings-beat/cZNRZI2RJRB
ImmunityBio (IBRX) stock is experiencing a five-day losing streak, but retail traders are optimistic about upcoming earnings, hoping strong Anktiva sales will reverse the trend. CEO Richard Adcock reported "incredibly strong" Anktiva sales, with Koyfin estimating quarterly revenue of $49.7 million, though retail expectations are higher. Investors are also watching for potential partnerships, buyouts, and the company's global expansion plans for Anktiva and its NK-cell platform.
Advertisement

ImmunityBio, Inc. (IBRX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/IBRX/seasonality/
The article provides a seasonal returns chart for ImmunityBio, Inc. (IBRX), showing the average monthly price return from 2016 to 2026. It also displays the current stock price and recent performance, along with links to other financial data for the company.

ImmunityBio, Inc. (IBRX) Seasonal returns chart - Yahoo Finance

https://sg.finance.yahoo.com/quote/IBRX/seasonality/
This Yahoo Finance article provides a seasonal returns chart for ImmunityBio, Inc. (IBRX), displaying the average monthly price return from 2016 to 2026. The page also shows current stock information, including the real-time Nasdaq price and pre-market activity. Users can view various financial data, news, and statistics related to IBRX.

Pancreatic Cancer Pipeline 2026: How New Mechanisms and Late-Stage Trials Are Reshaping the Treatment Paradigm

https://www.streetinsider.com/GetNews/Pancreatic+Cancer+Pipeline+2026%3A+How+New+Mechanisms+and+Late-Stage+Trials+Are+Reshaping+the+Treatment+Paradigm+%7C+Incyte%2C+AbbVie%2C+Ability+Pharma%2C+AB+Science%2C+AstraZeneca%2C+Eleison+Pharma%2C+ImmunityBio/27253948.html
A new report, "Pancreatic Cancer Pipeline Insight, 2026" by DelveInsight, highlights the global pancreatic cancer pipeline, which includes over 170 companies developing more than 200 therapeutic candidates. The report emphasizes the emergence of new mechanisms and late-stage trials that are significantly reshaping the treatment landscape, particularly focusing on RAS and KRAS G12D inhibitors like daraxonrasib and INCB161734. Recent regulatory approvals and breakthrough designations from the FDA for therapies like Rasonque (daraxonrasib) and olomorasib underscore the rapid advancements in addressing this aggressive cancer.

ImmunityBio Stock Has The Bull Case Changed After Trial Database Lock

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-stock-has-the-bull-case-changed-after-trial-data
ImmunityBio has reached database lock for its QUILT-2.005 trial and received FDA label expansion for ANKTIVA, broadening its bladder cancer treatment footprint. This development, coupled with an enlarged approved BCG-unresponsive population, strengthens the company's focus on ANKTIVA as a bladder cancer franchise. The investment narrative now pivots on execution, manufacturing capacity, and data readouts, with analysts projecting significant revenue and earnings growth by 2029.

IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave

https://es.tradingview.com/news/stocktwits:aab6b4cfc094b:0-ibrx-stock-rises-overnight-jim-cramer-backs-immunitybio-as-a-very-good-spec-amid-biotech-takeover-wave/
ImmunityBio (IBRX) shares rose after Jim Cramer endorsed the stock as a "very good spec," citing a wave of biotech acquisitions and the company's progress with its flagship drug, Anktiva. The FDA recently expanded Anktiva's approval for bladder cancer, and the company plans to submit another application in Q4, with a key data readout expected in November. Despite recent stock dips and mixed retail sentiment, Cramer highlighted the potential for significant returns in a speculative biotech play.
Advertisement

ImmunityBio locks trial database: ImmunityBio stock draws six Buy ratings

https://www.ad-hoc-news.de/boerse/news/corporate-news/immunitybio-locks-trial-database-immunitybio-stock-draws-six-buy-ratings/70423451
ImmunityBio has completed the database lock for its 366-patient registrational trial, with topline results for ANKTIVA plus BCG expected in November 2026. The company is also on track for a supplemental biologics license application in Q4 2026 for an expanded ANKTIVA indication. ImmunityBio's stock was trading at EUR 7.77 on October 27, 2026, and its third-quarter results are scheduled for November 3, 2026.

IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave

https://stocktwits.com/news-articles/markets/equity/ibrx-stock-jim-cramer-immunitybio-very-good-spec-biotech-takeover-wave/cZUI6h8RBzA
ImmunityBio (IBRX) shares rose after Jim Cramer called it a "very good spec," citing a wave of biotech acquisitions in the biotech sector. The company is advancing plans to expand the use of its flagship drug, Anktiva, in bladder cancer, with a November readout expected from a 366-patient trial and a planned fourth-quarter FDA filing. Anktiva has recently received expanded FDA approval and shows promising long-term data for BCG-unresponsive non-muscle invasive bladder cancer.

Weekly Recap: sBLA due Q4 2026 and ANKTIVA approval for papillary NMIBC

https://www.tradingview.com/news/tradingview:051db54fe9f7d:0-weekly-recap-sbla-due-q4-2026-and-anktiva-approval-for-papillary-nmibc/
ImmunityBio Inc (IBRX) announced that interim trial results support advancing to final efficacy analysis for a planned sBLA submission to the FDA in Q4 2026. Additionally, its FDA-approved drug ANKTIVA has received expanded approval for papillary-only NMIBC, with new data supporting its use in combination therapy with BCG.

ImmunityBio, Inc. Estimates – NASDAQ:IBRX

https://www.tradingview.com/symbols/NASDAQ-IBRX/financials-estimates/
This page provides financial data and analyst estimates for ImmunityBio, Inc. (NASDAQ: IBRX) through TradingView. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows for comparing actual results with average, high, and low estimates, and visualizing trends over time.

ImmunityBio (IBRX) Could Be 39% Undervalued After Key Bladder Cancer Trial Milestone

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-could-be-39-undervalued-after-key-bladder-c
ImmunityBio (IBRX) has completed the database lock for its pivotal QUILT-2.005 trial in BCG-naïve bladder cancer, moving towards final efficacy analysis and an expected supplemental FDA filing. Despite recent short-term volatility, the stock has seen significant longer-term momentum with a 327.72% year-to-date return. The company is currently considered 39% undervalued with a fair value pegged at $14.25, driven by ambitious growth and margin assumptions, including the integration of AI-driven tools.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement